AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China
Phase 3
Recruiting
- Conditions
- Lower Respiratory Tract Infection
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 800
- Registration Number
- NCT05110261
- Locations
- 🇨🇳
Research Site, Zhongshan, China
Study to Assess the Safety, Tolerability, and Pharmacokinetics (Movement of Drugs Within the Body) of AZD2693 in Healthy Participants
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 44
- Registration Number
- NCT05107336
- Locations
- 🇯🇵
Research Site, Sumida-ku, Japan
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
Phase 3
Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2025-04-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 732
- Registration Number
- NCT05104866
- Locations
- 🇬🇧
Research Site, Truro, United Kingdom
Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations
Active, not recruiting
- Conditions
- Non Small Cell Lung Cancer
- First Posted Date
- 2021-11-02
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 274
- Registration Number
- NCT05103605
- Locations
- 🇫🇷
Research Site, Villeurbanne, France
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT05101148
- Locations
- 🇪🇸
Research Site, Madrid, Spain
DOuBLED - Doubling Outcomes by Lung Cancer Early Diagnosis
Completed
- Conditions
- Pulmonary Nodules
- Interventions
- Diagnostic Test: Observational study
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 562
- Registration Number
- NCT05091437
- Locations
- 🇵🇦
Research Site, Panama, Panama
FASENRA Regulatory Postmarketing Surveillance in Korea
Completed
- Conditions
- Asthma, EGPA(Eosinophilic Granulomatosis With Polyangiitis)
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 51
- Registration Number
- NCT05091333
- Locations
- 🇰🇷
Research Site, Ulsan, Korea, Republic of
VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Subjects With Underlying Disease at High-risk for Worsening COVID-19
Terminated
- Conditions
- Prevention of Infectious Disease Caused by SARS-CoV-2
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4
- Registration Number
- NCT05084755
- Locations
- 🇯🇵
Research Site, Shizuoka, Japan
Pharmacokinetics, Immunogenicity, Safety and Tolerability of MEDI3506 in Health Chinese Participants
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: PlaceboBiological: MEDI3506
- First Posted Date
- 2021-10-07
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 39
- Registration Number
- NCT05070312
- Locations
- 🇨🇳
Research Site, Suzhou, China
To Assess the Pharmacokinetics, Safety, and Tolerability of AZD8233 in Participants With Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD) and Healthy Participants.
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3
- Registration Number
- NCT05065463
- Locations
- 🇵🇱
Research Site, Gdańsk, Poland
© Copyright 2025. All Rights Reserved by MedPath